Keywords: Contrast Agents, Lung, MRI, collagen, Protein-based contrast agent, lung fibrosis, IPF, COPD, lung cancer
Motivation: MRI diagnosis of lung has a limitation due to the air in the lungs which prevents the water signals. We use precision MRI to image the small lesions or fibrosis in the lung.
Goal(s): Our goal is to quantitatively stage the lung diseases by MRI contrast agents.
Approach: Our novel MRI contrast agent is biomarker specific which enables it target to the lung lesions or fibrosis.
Results: We are able to image the lung cancer and metastasis as well as lung fibrosis using our developed MRI contrast agent.
Impact: The imaging of lung tumor lesion or fibrosis is always hindered by the lung features. Our novol contrast agents enable us to image the lung diseases at early stages.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords